Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

ADVANCED REPRODUCTIVE MEDICINE & GYNECOLOGY OF HAWAII INC

UEI: L4XPC4VDZH53CAGE: 9KSU7

ADVANCED REPRODUCTIVE MEDICINE & GYNECOLOGY OF HAWAII INC is a federal contractor, registered under UEI L4XPC4VDZH53 and CAGE code 9KSU7. It has been awarded $65,746 in federal contracts. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services (hhs).

Contact Information

Registration and classification details

Registration

UEI Code

L4XPC4VDZH53

CAGE Code

9KSU7

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit Organization

NAICS Codes

621410Family Planning Centers(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

ADVANCED REPRODUCTIVE MEDICINE & GYNECOLOGY OF HAWAII INC provides specialized clinical services in reproductive endocrinology, infertility treatment, and comprehensive gynecological care. The organization delivers evidence-based fertility interventions including in vitro fertilization (IVF), intrau...

ADVANCED REPRODUCTIVE MEDICINE & GYNECOLOGY OF HAWAII INC provides specialized clinical services in reproductive endocrinology, infertility treatment, and comprehensive gynecological care. The organization delivers evidence-based fertility interventions including in vitro fertilization (IVF), intrauterine insemination (IUI), embryo cryopreservation, preimplantation genetic testing, and minimally invasive surgical procedures for reproductive disorders. Their technical expertise encompasses advanced embryology laboratory operations, hormonal modulation protocols, ultrasound-guided oocyte retrieval, and patient-centered fertility preservation strategies. Differentiators include personalized treatment planning, high-complexity laboratory standards, and integration of diagnostic imaging with molecular diagnostics to optimize reproductive outcomes. Award history is not available to inform agency-specific engagements, and no federal contract data is present to identify institutional partnerships or government-funded programs. Consequently, no definitive agency relationships or federal procurement patterns can be confirmed. The contractor operates under NAICS 621410, which classifies establishments providing outpatient fertility and gynecological services. In practice, this means the organization functions as a high-acuity outpatient clinic delivering diagnostic, therapeutic, and surgical reproductive health services, positioning itself within the specialized women’s health market segment. The business does not engage in broader healthcare systems integration, public health initiatives, or federal medical procurement channels based on available data. The entity is structured as a limited liability company (2L) and is headquartered in Honolulu, Hawaii. It holds no federal certifications such as 8(a), HUBZone, or WOSB. Its market presence is localized to the Hawaiian Islands, serving patients through private clinical practice rather than federal or state-funded healthcare programs. The organization’s operational model reflects a private, specialty medical practice focused on reproductive health outcomes within its regional service area.

Key performance metrics

Award counts and award dollars by type, as prime and as subcontractor.

Awards Count

1

All time

Active

0

Currently performing

Completed

1

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award analytics

Awards by agency, industry, year, award type, size, and place of performance.

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with ADVANCED REPRODUCTIVE MEDICINE & GYNECOLOGY OF HAWAII INC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for ADVANCED REPRODUCTIVE MEDICINE & GYNECOLOGY OF HAWAII INC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in ADVANCED REPRODUCTIVE MEDICINE & GYNECOLOGY OF HAWAII INC's top NAICS codes and agencies

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
The NIH Small Business Technology Transfer (STTR) grant, solicitation PA-27-102, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products in formal collaboration with non-profit research institutions. The program is designed to enhance health and reduce illness through a phased approach: Phase I focuses on establishing technical merit and feasibility, while Phase II advances the research toward commercialization. Eligible applicants include U.S.-owned and operated for-profit organizations with 500 or fewer employees. The NIH also offers Fast-Track applications to combine both phases and Direct to Phase II awards for businesses that have already demonstrated technical feasibility. Funding limits vary by the awarding NIH Institute or Center, with Phase I budgets typically ranging from 400,000 to 700,000 dollars and Phase II budgets reaching up to 3,000,000 dollars. Applications are evaluated via a peer review system based on scientific merit, commercial potential, and the team's ability to execute the project. While clinical trials are generally optional, they require a specific regulatory plan and adherence to strict safety and registration guidelines. Additionally, recipients must maintain active SAM and UEI registrations and comply with federal cybersecurity incident reporting requirements, including notifying the HHS of any breaches within 48 hours.
Department of Health and Human Services

POSTED

6 months ago

DEADLINE

in 5 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
The NIH, CDC, and FDA Small Business Innovation Research (SBIR) Grant, solicitation PA-27-100, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products. The program is structured in phases, with Phase I focusing on technical merit and feasibility and Phase II advancing the technology toward commercialization. Eligible applicants include for-profit U.S. businesses with no more than 500 employees. The funding opportunity accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with budget limits varying by participating institute, typically ranging from 400,000 to 700,000 dollars for Phase I and up to 3,000,000 dollars for Phase II. Applications are evaluated through a peer review system based on scientific and technical merit, significance, and the suitability of the business environment. While clinical trials are generally optional, they are prohibited for specific components, including all FDA participating components and several NIH institutes. Recipients must adhere to strict compliance requirements, including maintaining active SAM registration, disclosing foreign relationships, and implementing cybersecurity incident reporting procedures that notify agencies within 48 hours of discovery. The current solicitation remains open for applications until April 6, 2027.
Department of Health and Human Services

POSTED

6 months ago

DEADLINE

in 5 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The SBIR/STTR Commercialization Readiness Pilot (CRP) Program, under solicitation PAR-27-098, is a funding opportunity provided by the National Institutes of Health (NIH) to help U.S.-based small business concerns transition technology from late-stage development to full commercialization. This program specifically targets recipients of prior active or ended NIH SBIR/STTR Phase II or Phase IIB Strategic Breakthrough awards. The CRP supports activities that bridge the gap to market, including late-stage research and development, independent replication of key studies, manufacturing scale-up, and technical assistance such as regulatory strategy, intellectual property planning, and market research. While significant outsourcing to contract research organizations is permitted, the small business must maintain a substantial role in project oversight and management. Eligible projects may have a maximum performance period of three years, with budget ceilings varying by the participating NIH Institute or Center, ranging from 500,000 dollars to 2 million dollars, or following SBA guidelines for certain institutes. Applications are evaluated via the NIH peer review system based on scientific and technical merit, commercial potential, and relevance to program priorities. Key requirements for applicants include maintaining active SAM and UEI registrations and submitting a detailed regulatory plan and progress report. It is important to note that while clinical trials are generally optional, several NIH components, including the NHLBI, NIAID, and NIDDK, do not accept clinical trials under this specific funding opportunity. Additionally, funds cannot be used for patent or FDA filing fees, nor can they include separate Technical and Business Assistance funding.
Department of Health and Human Services

POSTED

6 months ago

DEADLINE

in 5 months
View Details